Clarity Medical Group Holding Ltd. has announced the establishment of a special investigation committee in response to certain allegations concerning two of its directors. The company has appointed PricewaterhouseCoopers Consulting Hong Kong Limited as the forensic adviser for the investigation. The allegations include the provision of funding by CEO Jiang Bo to a substantial shareholder for acquiring the company's shares, and the exclusion of certain directors in setting the scope of work for a reply to the Stock Exchange. The committee aims to deliver a preliminary investigation report to the board within eight weeks, although this timeline may be subject to change.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。